Matt Wilkinson
- News
Recycling CO2 to make plastic
A firm converting carbon dioxide into plastic is one of several receiving US funding to push research into creating useful products from the waste gas
- News
Bittersweet victory for GSK's Avandia
GlaxoSmithKline's diabetes drug looks set to remain on the market, but the firm is facing over £1.5 billion in various legal bills and settlements
- News
Biotechs plot path of least resistance
As big pharma turns its back on antibiotics in the wake of growing drug resistance, biotech companies are stepping in to develop new therapies
- News
Chemistry at Sussex under threat again
The future of the chemistry department at the University of Sussex, UK, has once again come under threat
- News
Nanotecture powers up
Nanotecture is gearing up to commercialise a new nanoporous material that it believes will find uses in a wide range of electricity storage applications
- News
CF wins turf war for Terra
CF Industries looks to have won the turf wars after its $4.7 billion bid beats Yara out of the bidding for Terra
- News
An agile future
Nick Roelofs, president of Agilent's life sciences group, discusses how the company is planning to ride the waves of the economic recovery
- Feature
Beyond terra firma
Matt Wilkinson reports on InXitu's award winning portable x-ray diffraction/x-ray fluorescence system
- News
Agrochem R&D strangled by red tape
Increasing burden of field trial data is hindering the development of new crop protection agents
- News
Merck joins the cost-cutting crowd
Following its merger with Schering-Plough, Merck & Co. has announced a 'merger restructuring plan' that will see 17,500 jobs cut
- News
Air Products to swallow Airgas
Air Products has launched a $7 billion takeover bid for rival gas supplier Airgas to gain access to the US bottled gas market
- News
More cuts pharma R&D budgets
GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets.